Rita Medical to Present at the Pacific Growth Equities Life Sciences Growth Conference
2006年6月10日 - 4:38AM
PRニュース・ワイアー (英語)
FREMONT, Calif., June 9 /PRNewswire-FirstCall/ -- RITA Medical
Systems, Inc. (NASDAQ:RITA), a publicly-traded medical device
company focused solely on cancer therapies, today announced that it
has been invited to present at the Pacific Growth Equities Life
Sciences Growth Conference, which will take place at the
InterContinental Mark Hopkins Hotel in San Francisco. The Company
is scheduled to discuss its business strategy and historical
financial performance on Monday, June 12, 2006 at 10:00 a.m.
Pacific Time. Attendance at the conference is by invitation only.
RITA Medical will offer a live audio webcast of its presentation
which may be accessed at the Company's website at
http://www.ritamedical.com/. An archived replay of the presentation
will also be available approximately three hours following the live
presentation and will also be available at
http://www.ritamedical.com/. About RITA Medical Systems, Inc. RITA
Medical Systems develops, manufactures and markets innovative
products for cancer patients including radiofrequency ablation
(RFA) systems and embolization products for treating cancerous
tumors as well as percutaneous vascular and spinal access systems.
The Company's oncology product lines include implantable ports,
some of which feature its proprietary Vortex(R) technology;
tunneled central venous catheters; and safety infusion sets and
peripherally inserted central catheters used primarily in cancer
treatment protocols. The radiofrequency product line also includes
the HABIB 4X resection device, which coagulates a "surgical
resection plane" and is designed to facilitate a fast dissection in
order to minimize blood loss and blood transfusion during surgery.
The proprietary RITA RFA system uses radiofrequency energy to heat
tissue to a high enough temperature to ablate it or cause cell
death. In March 2000, RITA became the first RFA company to receive
specific FDA clearance for unresectable liver lesions in addition
to its previous general FDA clearance for the ablation of soft
tissue. In October 2002, RITA again became the first company to
receive specific FDA clearance, this time for the palliation of
pain associated with metastatic lesions involving bone. The Company
also distributes LC Bead embolic microspheres in the United States.
The LC Bead microspheres are injected into selected vessels to
block the blood flow feeding a tumor, causing it to shrink over
time, and are often used in combination with radiofrequency
ablation (RFA). The RITA Medical Systems website is at
http://www.ritamedical.com/. DATASOURCE: RITA Medical Systems, Inc.
CONTACT: Investors, Doug Sherk, , or Jennifer Beugelmans, both at
+1-415-896-6820, or Media, Steve DiMattia, +1-646-277-8706, or ,
all of EVC Group for RITA Medical Systems, Inc.; Joseph DeVivo,
President and CEO of RITA Medical Systems, Inc., +1-510-771-0400
Web site: http://www.ritamedical.com/
Copyright
Rita Medical (NASDAQ:RITA)
過去 株価チャート
から 5 2024 まで 6 2024
Rita Medical (NASDAQ:RITA)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Rita Medical Systems (ナスダック市場): 0 recent articles
その他のRita Medical Systems (MM)ニュース記事